We are live on ! Find out more
COEPW

Coeptis Therapeutics Warrants

Delisted

COEPW was delisted on the 24th of April, 2026.

17 hedge funds and large institutions have $27.4K invested in Coeptis Therapeutics Warrants in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1717 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

1.19% less ownership

Funds ownership: 5.67%4.47% (-1.2%)

55% less capital invested

Capital invested by funds: $61.3K → $27.4K (-$33.9K)

Holders
17
Holders Change
Holders Change %
0%
% of All Funds
0.24%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
3
Reduced
3
Closed
1
Calls
Puts
Net Calls
Net Calls Change

COEPW Hedge Fund Activity: Q3 2024 in Review

17 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q3 2024, worth a combined $27.4K — down 55% from $61.3K a quarter earlier.

Fund positioning in COEPW was balanced in Q3 2024: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 3 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $5. The largest seller was Meteora Capital, cutting an estimated $3.66K.

  • 17 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $27.4K of Coeptis Therapeutics Warrants stock for Q3 2024, down 55% quarter-over-quarter.
  • 1 fund opened new Coeptis Therapeutics Warrants positions in Q3 2024 and 1 closed out, a net change of 0 holders.
  • The largest Coeptis Therapeutics Warrants buyer in Q3 2024 was Citadel Advisors, an estimated $5 added.
  • The largest Coeptis Therapeutics Warrants seller in Q3 2024 was Meteora Capital, an estimated $3.66K sold.

Based on aggregated 13F filings for Q3 2024.